Vitanza, Nicholas A. http://orcid.org/0000-0002-3966-4985
Johnson, Adam J. http://orcid.org/0000-0002-9967-8959
Wilson, Ashley L.
Brown, Christopher
Yokoyama, Jason K.
Künkele, Annette http://orcid.org/0000-0002-8406-5412
Chang, Cindy A.
Rawlings-Rhea, Stephanie
Huang, Wenjun http://orcid.org/0000-0001-8948-7262
Seidel, Kristy
Albert, Catherine M.
Pinto, Navin http://orcid.org/0000-0002-8775-6710
Gust, Juliane
Finn, Laura S.
Ojemann, Jeffrey G.
Wright, Jason
Orentas, Rimas J.
Baldwin, Michael
Gardner, Rebecca A.
Jensen, Michael C. http://orcid.org/0000-0001-7477-3063
Park, Julie R. http://orcid.org/0000-0002-6777-9165
Article History
Received: 22 December 2020
Accepted: 25 May 2021
First Online: 12 July 2021
Competing interests
: M.C.J. has interests in Umoja Biopharma and Juno Therapeutics, a Bristol Myers Squibb company. He is a seed investor and holds ownership equity in Umoja, serves as a member of the Umoja Joint Steering Committee and is a Board Observer of the Umoja Board of Directors. M.C.J. also holds patents, some of which are licensed to Umoja Biopharma and Juno Therapeutics. R.A.G. serves on a study steering committee for and is an inventor on a patent licensed to Juno Therapeutics and has served on advisory boards for Novartis. A.J.J. is an inventor on issued and pending patents related to CAR T cell therapies, and R.J.O. receives research support from Lentigen Technology, a Miltenyi Biotec company, and is a consultant for Umoja Biopharma. All other authors declare no competing financial interests.